CA3128392A1 - Antibodies recognizing tau - Google Patents

Antibodies recognizing tau Download PDF

Info

Publication number
CA3128392A1
CA3128392A1 CA3128392A CA3128392A CA3128392A1 CA 3128392 A1 CA3128392 A1 CA 3128392A1 CA 3128392 A CA3128392 A CA 3128392A CA 3128392 A CA3128392 A CA 3128392A CA 3128392 A1 CA3128392 A1 CA 3128392A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
occupied
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128392A
Other languages
English (en)
French (fr)
Inventor
Philip James Dolan, Iii
Tarlochan S. Nijjar
Svetlana Alexander
Robin Barbour
Stephen Jed TAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CA3128392A1 publication Critical patent/CA3128392A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3128392A 2019-02-08 2020-02-07 Antibodies recognizing tau Pending CA3128392A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962803334P 2019-02-08 2019-02-08
US62/803,334 2019-02-08
US201962813124P 2019-03-03 2019-03-03
US62/813,124 2019-03-03
US201962855434P 2019-05-31 2019-05-31
US62/855,434 2019-05-31
PCT/US2020/017357 WO2020163817A1 (en) 2019-02-08 2020-02-07 Antibodies recognizing tau

Publications (1)

Publication Number Publication Date
CA3128392A1 true CA3128392A1 (en) 2020-08-13

Family

ID=71947192

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128392A Pending CA3128392A1 (en) 2019-02-08 2020-02-07 Antibodies recognizing tau

Country Status (14)

Country Link
US (1) US20220275067A1 (enExample)
EP (1) EP3921343A4 (enExample)
JP (2) JP7681316B2 (enExample)
KR (1) KR20210125037A (enExample)
CN (2) CN113597431B (enExample)
AU (1) AU2020219374B2 (enExample)
BR (1) BR112021015501A2 (enExample)
CA (1) CA3128392A1 (enExample)
CO (1) CO2021011140A2 (enExample)
IL (1) IL285444A (enExample)
MX (1) MX2021009440A (enExample)
PE (1) PE20211709A1 (enExample)
SG (1) SG11202106717PA (enExample)
WO (1) WO2020163817A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
SG11202106717PA (en) * 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3226301A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法
WO2025198916A1 (en) * 2024-03-16 2025-09-25 Abbvie Inc. Anti-tau antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018546A2 (en) * 1999-09-09 2001-03-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of 'paired helical filaments'
US8754034B2 (en) * 2009-02-06 2014-06-17 The Regents Of The University Of California Structure-based design of peptide inhibitors of amyloid fibrillation
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
WO2012106363A2 (en) * 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
WO2013059786A1 (en) * 2011-10-21 2013-04-25 The Ohio State University Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014165271A2 (en) * 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
NZ775762A (en) * 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US11319372B2 (en) * 2017-02-21 2022-05-03 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
SG11202106717PA (en) * 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau

Also Published As

Publication number Publication date
CO2021011140A2 (es) 2021-09-20
BR112021015501A2 (pt) 2021-10-19
MX2021009440A (es) 2021-09-10
PE20211709A1 (es) 2021-09-01
JP7843068B2 (ja) 2026-04-09
EP3921343A4 (en) 2022-12-14
CN113597431B (zh) 2025-02-21
KR20210125037A (ko) 2021-10-15
EP3921343A1 (en) 2021-12-15
WO2020163817A1 (en) 2020-08-13
IL285444A (en) 2021-09-30
CN113597431A (zh) 2021-11-02
JP2022520672A (ja) 2022-03-31
AU2020219374A1 (en) 2021-07-01
CN119954947A (zh) 2025-05-09
US20220275067A1 (en) 2022-09-01
JP2025029046A (ja) 2025-03-05
SG11202106717PA (en) 2021-07-29
JP7681316B2 (ja) 2025-05-22
AU2020219374B2 (en) 2026-07-02

Similar Documents

Publication Publication Date Title
JP7843068B2 (ja) タウを認識する抗体
US20230250161A1 (en) Antibodies recognizing tau
JP7587304B2 (ja) タウ認識抗体
US20240209073A1 (en) Antibodies recognizing tau
AU2019377595B2 (en) Antibodies recognizing tau
AU2017259039B2 (en) Antibodies recognizing tau
AU2018448903B2 (en) Antibodies recognizing tau
HK40120191A (en) Antibodies recognizing tau

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260114